BMY•benzinga•
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Summary
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 4, 2024 by benzinga